Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments
Stephen P. Arnerić, Volker D. Kern, Diane Stephenson
Biochemical Pharmacology (2018) Vol. 151, pp. 291-306
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

The “rights” of precision drug development for Alzheimer’s disease
Jeffrey L. Cummings, Howard Feldman, Philip Scheltens
Alzheimer s Research & Therapy (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 204
Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
Kevin Mullane, Michael Williams
Biochemical Pharmacology (2020) Vol. 177, pp. 113945-113945
Closed Access | Times Cited: 86
Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
René Bruno, Dean Bottino, Dinesh P. de Alwis, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 8, pp. 1787-1795
Open Access | Times Cited: 72
Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
M. Catarina Silva, Stephen J. Haggarty
Annals of the New York Academy of Sciences (2019) Vol. 1471, Iss. 1, pp. 18-56
Open Access | Times Cited: 71
Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical Trials
Sílvia Zaragoza Domingo, Jordi Alonso, Montse Ferrer, et al.
European Neuropsychopharmacology (2024) Vol. 83, pp. 32-42
Open Access | Times Cited: 4
Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases
Andrea I. Krahn, Carrow I. Wells, David H. Drewry, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 13, pp. 1871-1886
Open Access | Times Cited: 29
Intellectual Property Rights in Neuroprotective Biomaterials
Chandrabhan Prajapati, Prabhash Nath Tripathi, Saloni Sood, et al.
(2025), pp. 251-269
Closed Access
Assessing central nervous system drug delivery
Margareta Hammarlund‐Udenaes, Irena Loryan
Expert Opinion on Drug Delivery (2025)
Closed Access
Computational Attitude to Drug Discovery in Parkinson's Disease
Chitra Vellapandian, S. Ankul Singh, Swathi Suresh, et al.
(2025), pp. 271-311
Closed Access
The Use of ex Vivo Rodent Platforms in Neuroscience Translational Research With Attention to the 3Rs Philosophy
Laura Lossi, Adalberto Merighi
Frontiers in Veterinary Science (2018) Vol. 5
Open Access | Times Cited: 31
Alzheimer’s disease (AD) therapeutics – 2: Beyond amyloid – Re-defining AD and its causality to discover effective therapeutics
Kevin Mullane, Michael Williams
Biochemical Pharmacology (2018) Vol. 158, pp. 376-401
Closed Access | Times Cited: 29
Mental health dished up—the use of iPSC models in neuropsychiatric research
Rhiannon V. McNeill, Georg Ziegler, Franziska Radtke, et al.
Journal of Neural Transmission (2020) Vol. 127, Iss. 11, pp. 1547-1568
Open Access | Times Cited: 27
APOE-ε4 allele[s]-associated adverse events reported from placebo arm in clinical trials for Alzheimer's disease: implications for anti-amyloid beta therapy
Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Frontiers in Dementia (2024) Vol. 2
Open Access | Times Cited: 3
Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes
Adam C. Raikes, Gerson D. Hernandez, Dawn Matthews, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 12
Emerging challenges and opportunities for drug and drug product registrations
Ajay Kumar Pal, Khushali Nathani, Madhura Mulkutkar, et al.
Elsevier eBooks (2024), pp. 501-526
Closed Access | Times Cited: 2
Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery
Shi-Dong Chen, Hong‐Qi Li, Mei Cui, et al.
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 9, pp. 1081-1094
Closed Access | Times Cited: 13
Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington’s Disease
Ariana P. Mullin, Diane Corey, Emily C. Turner, et al.
Clinical and Translational Science (2020) Vol. 14, Iss. 1, pp. 214-221
Open Access | Times Cited: 13
Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson’s Disease
Gleyce Fonseca Cabral, Ana Paula Schaan, Giovanna C. Cavalcante, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9839-9839
Open Access | Times Cited: 11
Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries
Lucia Gozzo, Giovanni Luca Romano, Serena Brancati, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 7
Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies
Stephen R. Karpen, Jessica L. Dunne, Brigitte I. Frohnert, et al.
Diabetologia (2022) Vol. 66, Iss. 3, pp. 415-424
Open Access | Times Cited: 7
Body of evidence and approaches applied in the clinical development programme of fixed‐dose combinations in the European Union from 2010 to 2016
Asbjørn Nøhr‐Nielsen, Marie L. De Bruin, Mikael S. Thomsen, et al.
British Journal of Clinical Pharmacology (2019) Vol. 85, Iss. 8, pp. 1829-1840
Open Access | Times Cited: 9
Open Datasets in Human Activity Recognition Research—Issues and Challenges: A Review
Gulzar Alam, Ian McChesney, Peter Nicholl, et al.
IEEE Sensors Journal (2023) Vol. 23, Iss. 22, pp. 26952-26980
Open Access | Times Cited: 3
Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach
Jeffrey L. Cummings
Dementia and Geriatric Cognitive Disorders (2020) Vol. 49, Iss. 1, pp. 22-37
Closed Access | Times Cited: 7
Corneal confocal microscopy demonstrates sensory nerve loss in children with autism spectrum disorder
Adnan Khan, Madeeha Kamal, Abdula Alhothi, et al.
PLoS ONE (2023) Vol. 18, Iss. 7, pp. e0288399-e0288399
Open Access | Times Cited: 2
Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues
Luca Pani, Richard S.E. Keefe
Schizophrenia Research Cognition (2019) Vol. 18, pp. 100155-100155
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top